Search

Displaying results 3461 - 3470 of 6076 in total
  1. Drug

    Combretastatin

    go.drugbank.com/drugs/DB12596
    Investigational

    Combretastatin has been investigated for the treatment of Anaplastic Thyroid Cancer.

  2. Drug

    Palmidrol

    go.drugbank.com/drugs/DB14043
    InvestigationalNutraceutical

    Palmidrol is available for human use as a supplement (400 mg capsules) and as food for medical purposes In Italy and Spain (300 mg and 600 mg tablets).

  3. Drug

    MD05

    go.drugbank.com/drugs/DB06375
    Investigational

    MD05 is a beta-tricalcium phosphate (beta-TCP) coated with recombinant human growth/differentiation factor-5 (rhGDF-5).

  4. Drug

    Scriptaid

    go.drugbank.com/drugs/DB17053
    Experimental

    Scriptaid is a histone deacetylase (HDAC) inhibitor researched for its anti-tumor properties.[A253127]

  5. Drug

    Dapiglutide

    go.drugbank.com/drugs/DB19182
    Investigational

    Dapiglutide is under investigation in clinical trial NCT05788601 (Dapiglutide for the Treatment of Obesity).

  6. Drug

    Biochanin A

    go.drugbank.com/drugs/DB15334
    Experimental

    Biochanin A is under investigation in clinical trial NCT02174666 (Isoflavone Treatment for Postmenopausal Osteopenia.).

  7. Drug

    Vidofludimus

    go.drugbank.com/drugs/DB15446
    Investigational

    Vidofludimus is under investigation in clinical trial NCT03722576 (Vidofludimus Calcium for Primary Sclerosing Cholangitis).

  8. Drug

    Demcizumab

    go.drugbank.com/drugs/DB12734
    Investigational

    Demcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung.

  9. Drug

    N-omega-nitro-L-arginine methyl ester

    go.drugbank.com/drugs/DB12750
    Investigational

    L-NAME has been investigated for the treatment of Hypotension and Spinal Cord Injury.

  10. Drug

    Miravirsen

    go.drugbank.com/drugs/DB12851
    Investigational

    Miravirsen has been investigated for the treatment of Hepatitis C and Hepatitis C, Chronic.